Patents by Inventor Xianfeng Lin

Xianfeng Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240050577
    Abstract: The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of one or more CDK protein in a cell and are thus useful for treating, inhibiting, and preventing CDK-associated diseases, disorders and conditions, including cancers.
    Type: Application
    Filed: April 26, 2023
    Publication date: February 15, 2024
    Inventors: Jiasheng LV, Yao LIU, Xiangyang LI, Xianfeng LIN, Qisheng LIU, Yuanhong GU, Kang DU, Zhihong ZHANG, Mengchao SHI, Yuhua ZHANG, Jian GE, Tianlun ZHOU, Xiangsheng YE, Xianqi KONG, Dawei CHEN
  • Publication number: 20230416238
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X, Cy and R1 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230331715
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R3 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 19, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Jianping WANG, Hongying YUN, Xiufang ZHENG
  • Publication number: 20230312491
    Abstract: The present invention provides novel compounds having the general formula (I): wherein R1 to R3 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 5, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286968
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, L1, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286930
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286927
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Publication number: 20230286969
    Abstract: The present invention provides novel compounds having the general formula: wherein A1 to A4, X1, Rx, Ry, Cy, L and R1 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xianfeng LIN, Hongying YUN, Bo ZHANG, Xiufang ZHENG
  • Patent number: 11684696
    Abstract: A gradient mineralized cancellous bone matrix material and a preparation method thereof are provided, and the preparation method includes: processing naturally-derived bone tissue with an immunogenicity removal treatment for decellularization, and processing an obtained decellularzed bone with a gradient demineralization treatment to obtain the gradient mineralized cancellous bone matrix material. The present invention expands a porosity of the bone matrix material and a collagen exposure degree on a surface thereof, which effectively releases growth factors and improves adhesion of the material to the cells, so as to up-regulate genes and proteins related to cell regeneration.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: June 27, 2023
    Assignees: SIR RUN RUN SHAW HOSPITAL ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE, ZHEJIANG DISAI BIOTECHNOLOGY CO., LTD
    Inventors: Xianfeng Lin, Shijie Liu, Yiyun Wang, Yazhi Lu, Shunwu Fan
  • Publication number: 20220313609
    Abstract: A nano composite material aiming at an acidic sealing zone in osteoclasts and a preparation method thereof are provided. The nano composite material aiming at the acidic sealing zone in the osteoclasts includes a nano material, bone-targeting molecules, and a compound able to react with the acidic sealing zone in the osteoclasts, wherein: after being modified by the bone-targeting molecules, the nano material is loaded with the compound able to react with the acidic sealing zone in the osteoclasts. Through accurate mature osteoclast targeting and chemically regulated biocascade effects, the osteoclasts are inhibited, which provides a new idea and a new tool for drug therapy of abnormal osteoclast activation.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 6, 2022
    Inventors: Xianfeng Lin, Chenhui Gu, Qingqing Wang, Shunwu Fan
  • Publication number: 20210121605
    Abstract: A gradient mineralized cancellous bone matrix material and a preparation method thereof are provided, and the preparation method includes: processing naturally-derived bone tissue with an immunogenicity removal treatment for decellularization, and processing an obtained decellularzed bone with a gradient demineralization treatment to obtain the gradient mineralized cancellous bone matrix material. The present invention expands a porosity of the bone matrix material and a collagen exposure degree on a surface thereof, which effectively releases growth factors and improves adhesion of the material to the cells, so as to up-regulate genes and proteins related to cell regeneration.
    Type: Application
    Filed: March 12, 2019
    Publication date: April 29, 2021
    Inventors: Xianfeng Lin, Shijie Liu, Yiyun Wang, Yazhi LU, Shunwu Fan
  • Publication number: 20200339603
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: April 29, 2020
    Publication date: October 29, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Yimin Hu, Chengang Zhou, Mingwei Zhou, Houguang Shi, Yongqiang Liu, Hong Shen, Maarten Vercruysse, Shixiang Yan, Xuefei Tan, Xianfeng Lin, Fabian Dey
  • Patent number: 10683299
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: June 16, 2020
    Assignee: HOFFMANN LA ROCHE INC.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Patent number: 10662203
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yimin Hu, Chengang Zhou, Mingwei Zhou, Houguang Shi, Yongqiang Liu, Hong Shen, Maarten Vercruysse, Shixiang Yan, Xuefei Tan, Xianfeng Lin, Fabian Dey
  • Patent number: 10597380
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John G. Cumming, Xianfeng Lin, Haixia Liu, Isabel Najera, Zongxing Qiu, Virginie Sandrin, Guozhi Tang, Guolong Wu
  • Publication number: 20200062753
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 5, 2019
    Publication date: February 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu
  • Patent number: 10428069
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: October 1, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu
  • Publication number: 20190248792
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Application
    Filed: January 14, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xingchun Han, Xianfeng Lin, Hong Shen, Taishan Hu, Zhisen Zhang
  • Publication number: 20190127349
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: John G. CUMMING, Xianfeng LIN, Haixia LIU, Isabel NAJERA, Zongxing QIU, Virginie SANDRIN, Guozhi TANG, Guolong WU
  • Publication number: 20180370969
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu